Loading...
Market
How many new drug discoveries will be announced by Recursion Pharmaceuticals and Exscientia post-merger by December 31, 2024?
3
Resolution / Starting Odds
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Official press releases from Recursion Pharmaceuticals or Exscientia, announcements at biotech conferences, publications in scientific journals
Story
Recursion and Exscientia to Merge in $688 Million All-Stock Deal
Aug 8, 2024, 12:02 PM
Recursion Pharmaceuticals and Exscientia have entered a definitive agreement to merge, creating a global leader in technology-enabled drug discovery. The merger, valued at $688 million, is an all-stock deal that will combine Recursion's high throughput target biology and supercomputing capabilities with Exscientia's generative AI drug design and chemistry automation. The collaboration is expected to enhance the companies' end-to-end capabilities in the biotech sector, marking a significant milestone in the use of AI in drug development.
View original story
Similar markets
Yes • 50%
No • 50%
Partnership with a major pharmaceutical company • 25%
Acquisition by a major pharmaceutical company • 25%
Partnership with a tech company • 25%
No partnership or acquisition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
Yes • 50%
No • 50%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
No new partnerships • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
None • 25%
One • 25%
Two • 25%
Three or more • 25%